Frank Daniel Martos-BenÃtez
“Hermanos Ameijeiras†Hospital, Cuba
Title: Docetaxel-induced acute respiratory distress syndrome: A report of ten cases
Biography
Biography: Frank Daniel Martos-BenÃtez
Abstract
Docetaxel is a commonly used drug in chemotherapy for the treatment of cancer patients such as breast and lung cancer patients. Docetaxel-associated pulmonary fibrosis had been reported. Pulmonary gas exchange can be affected in severe cases; however, docetaxel-induced acute respiratory distress syndrome is a life-threatening complication no informed before. We report ten cases admitted in an oncological intensive care unit (ICU) with acute respiratory distress syndrome (ARDS) after beginning docetaxel chemotherapy. The mean age was 59,8 years (SD 10,2 years) and all patients were female. The PaO2, SaO2, PaO2/ FiO2 and PaCO2 at ICU admission was 75,1 mmHg (SD 33,0 mmHg), 81,5% (SD 11,4%), 141 mmHg (SD 74,6 mmHg) and 46,5 mmHg (SD 17,2 mmHg), respectively. Sexty percent developed a severe ARDS (PaO2/ FiO2 < 100 mmHg). Invasive ventilatory support was needed in 70% of cases. The mean peak pressure, plateau pressure, compliance and airway resistance at ventilation day was 35,2 cmH2O (DE 1,3 cmH2O), 31,6 cmH2O (DE 1,3 cmH2O), 19,8 ml/cmH2O (8,6 ml/cmH2O) and 44,5 cmH2O/L/seg. (10,0 cmH2O/L/seg.), respectively. The ICU mortality rate was 70%. Docetaxel-induced ARDS is an uncommon type of ARDS, but it should be taken into account in cancer patients treated with that drug.